A novel transmembrane glycoprotein cancer biomarker present in the X chromosome

Cancer Genomics and Proteomics

Volumn 11, Issue 2, 2014, Pages 81-92

  Delgado, Ana Paula ^a   Hamid, Sheilin ^a   Brandao, Pamela ^a   Narayanan, Ramaswamy ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

'dark matter' of the genome; Biomarkers; Cell trafficking; ORF; Secreted protein; Serum protein; Signal peptide; Uncharacterized proteins; Vesicular transport; X chromosome

Indexed keywords

GLYCOPROTEIN; MEMBRANE PROTEIN; TUMOR MARKER; SGPX PROTEIN, HUMAN;

ARTICLE; BIOINFORMATICS; BRAIN CANCER; CXORF66 GENE; DOWN REGULATION; GENE; GENE CONTROL; GENE DOSAGE; GENE EXPRESSION; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; NEUTROPHIL; OPEN READING FRAME; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEOMICS; SECRETED GLYCOPROTEIN IN CHROMOSOME X GENE; UPREGULATION; X CHROMOSOME; CHEMICAL STRUCTURE; CHEMISTRY; COPY NUMBER VARIATION; GENETICS; META ANALYSIS; METABOLISM; NEOPLASM; NUCLEOTIDE SEQUENCE; PROTEIN TERTIARY STRUCTURE;

CHROMOSOMES, HUMAN, X; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; TUMOR MARKERS, BIOLOGICAL;

EID: 84901432647     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Lander ES, Linton LM, Birren B et al: and International Human Genome Sequencing, Consortium Initial sequencing and analysis of the human genome. Nature 409(6822): 860-921, 2001.
2. Venter JC, Adams MD, Myers EW et al: The sequence of the human genome. Science 291(5507): 1304-1351, 2001.
3. Narayanan R: Bioinformatics approaches to cancer gene discovery. Meth Mol Biol 360: 13-31, 2007.
4. Scheurle D, DeYoung MP, Binninger DM, Page H, Jahanzeb M and Narayanan R: Cancer gene discovery using digital differential display. Cancer research 60(15): 4037-4043, 2000.
5. De Young MP, Damania H, Scheurle D, Zylberberg C and Narayanan R: Bioinformatics-based discovery of a novel factor with apparent specificity to colon cancer. In Vivo 16(4): 239-248, 2002.
6. Schmitt AO: Mining expressed sequence tag (EST) libraries for cancer-associated genes. Methods in molecular biology 76: 89-98, 2010.
7. Alfoldi J and Lindblad-Toh K: Comparative genomics as a tool to understand evolution and disease. Genome Res 23(7): 1063-1068, 2013.
8. Lauriola M, Ugolini G, Rosati G, Zanotti S, Montroni I, Manaresi A et al: Identification by a Digital Gene Expression Displayer (DGED) and test by RT-PCR analysis of new mRNA candidate markers for colorectal cancer in peripheral blood. International J Oncol 37(2): 519-25, 2010.
9. Hopkins AL and Groom CR: The druggable genome. Nature reviews Drug Discovery 1(9): 727-730, 2002.
10. Pertea M and Salzberg SL: Between a chicken and a grape: estimating the number of human genes. Genome Biology 11(5): 206, 2010.
11. Nagano T and Fraser P: No-nonsense functions for long noncoding RNAs. Cell 145(2): 178-181, 2011.
12. Brylinski M: Exploring the "dark matter" of a mammalian proteome by protein structure and function modeling. Proteome Science 11(1): 47, 2013.
13. Blaxter M: Genetics. Revealing the dark matter of the genome. Science 330(6012): 1758-1759, 2010.
14. Hauptman N and Glavac D: MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiology and oncology 47(4): 311-318, 2013.
15. Mak L, Liggi S, Tan L, Kusonmano K, Rollinger JM, Koutsoukas A, Glen RC and Kirchmair J: Anticancer drug development: computational strategies to identify and target proteins involved in cancer metabolism. Current pharmaceutical design 19(4): 532-577, 2013.
16. Natrajan R and Wilkerson P: From integrative genomics to therapeutic targets. Cancer Res 7 3(12): 3483-488, 2013.
17. Nevins JR and Potti A: Mining gene expression profiles: expression signatures as cancer phenotypes. Nature Reviews Genetics 8(8): 601-609, 2007.
18. Delgado A.P BP, Hamid S and Narayanan R: Mining the dark matter of the cancer proteome for novel biomarkers. Current Cancer Therapy Review 10, 2014 (in press).
19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery 2(5): 401-404, 2012.
20. Halling-Brown MD, Bulusu KC, Patel M, Tym JE and Al-Lazikani B: canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res 40(Database issue): D947-956, 2012.
21. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids Res 39(Database issue): D945-950, 2011.
22. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB et al: Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9(2): 166-180, 2007.
23. Parkinson H, Sarkans U, Shojatalab M, Abeygunawardena N, Contrino S, Coulson R et al: ArrayExpress-a public repository for microarray gene expression data at the EBI. Nucleic acids Res 33(Database issue): D553-555, 2005.
24. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M et al: Towards a knowledge-based Human Protein Atlas. Nature biotechnology 28(12): 1248-1250, 2010.
25. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S et al: Human Protein Reference Database-2009 update. Nucleic acids Res 37(Database issue): D767-772, 2009.
26. Kolker E, Higdon R, Haynes W, Welch D, Broomall W, Lancet D et al: MOPED: Model Organism Protein Expression Database. Nucleic acids Res 40(Database issue): D1093-1099, 2012.
27. Rost B, Yachdav G and Liu J: The PredictProtein server. Nucleic acids research 32(Web Server issue): W321-326, 2004.
28. Cong Q and Grishin NV: MESSA: MEta-Server for protein Sequence Analysis. BMC Biol 10: 82, 2012.
29. Workman P, Al-Lazikani B and Clarke PA: Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Current opinion in pharmacology 13(4): 486-496, 2013.
30. Landry Y and Gies JP: Drugs and their molecular targets: an updated overview. Fundamental & Clinical Pharmacology 22(1): 1-18, 2008.
31. Orth AP, Batalov S, Perrone M and Chanda SK. The promise of genomics to identify novel therapeutic targets. Expert opinion on therapeutic targets 8(6): 587-596, 2004.
32. Zendman AJ, Zschocke J, van Kraats AA, de Wit NJ, Kurpisz M, Weidle UH et al: The human SPANX multigene family: genomic organization, alignment and expression in male germ cells and tumor cell lines. Gene 309(2): 125-133, 2003.
33. Vasudevan SA, Russell HV, Okcu MF, Burlingame SM, Liu ZJ, Yang J et al: Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma. Journal of pediatric surgery 42(1): 148-152, 2007.
34. Ofran Y, Rost B. ISIS: interaction sites identified from sequence. Bioinformatics 23(2): e13-16, 2007.
35. Guan R, Dai H, Harrison SC and Kirchhausen T: Structure of the PTEN-like region of auxilin, a detector of clathrin-coated vesicle budding. Structure 18(9): 1191-1198, 2010.
36. Lappalainen T, Sammeth M, Friedlander MR, t Hoen PA, Monlong J, Rivas MA et al: Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501(7468): 506-511, 2013.
37. Westbrook VA, Schoppee PD, Diekman AB, Klotz KL, Allietta M, Hogan KT et al: Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clinical cancer research: an official journal of the American Association for Cancer Res 10(1 Pt 1): 101-12, 2004.
38. Salemi M, Calogero AE, Zaccarello G, Castiglione R, Cosentino A, Campagna C et al: Expression of SPANX proteins in normal prostatic tissue and in prostate cancer. European journal of histochemistry: EJH 54(3): e41, 2010.
39. Li K, Wang L, Cheng J, Zhang L, Duan H, Lu Y et al: Screening and cloning gene of hepatocyte protein interacting with hepatitis C virus core protein. Chin J Exp Clin Virol 16(4): 351-353, 2002. (in Chinese).
40. Ma X, Wang YW, Zhang MQ and Gazdar AF: DNA methylation data analysis and its application to cancer research. Epigenomics 5(3): 301-316, 2013.
41. Gnyszka A, Jastrzebski Z and Flis S: DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 33(8): 2989-2996, 2013.
42. Villicana C, Cruz G and Zurita M: The basal transcription machinery as a target for cancer therapy. Cancer cell international 14(1): 18, 2014.
43. Qi W, Liang W, Jiang H and Miuyee Waye M: The function of miRNA in hepatic cancer stem cell. BioMed Research International 2: 358902, 2013.
44. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation 36(3): 131-149, 2003.
45. Borssen M, Palmqvist L, Karrman K, Abrahamsson J, Behrendtz M, Heldrup J et al: Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PloS one 8(6): e65373, 2013.
46. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B et al: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research 16(5): 1509-1519, 2010.
47. Casimiro MC, Velasco-Velazquez M, Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert opinion on Investigational Drugs 23(3): 295-304, 2014.
48. Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 65(22): 10413-10422, 2005.
49. Huret JL, Ahmad M, Arsaban M, Bernheim A, Cigna J, Desangles F et al: Atlas of genetics and cytogenetics in oncology and haematology in 2013. Nucleic Acids Res 41(Database issue): D920-4, 2013.
50. Liao DJ, Du QQ, Yu BW, Grignon D and Sarkar FH: Novel perspective: focusing on the X chromosome in reproductive cancers. Cancer Investigation 21(4): 641-658, 2003.
51. Jager N, Schlesner M, Jones DT, Raffel S, Mallm JP, Junge KM et al: Hypermutation of the inactive X chromosome is a frequent event in cancer. Cell 155(3): 567-581, 2013.
52. Astle MV, Horan KA, Ooms LM and Mitchell CA: The inositol polyphosphate 5-phosphatases: traffic controllers, waistline watchers and tumour suppressors? Biochemical Society Symposium 74: 161-181, 2007.
53. Koga M, Shichijo S, Yamada A, Ashihara J, Sawamizu H, Kusukawa J et al: Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL. Tissue Antigens 61(2): 136-145, 2003.